alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1
 
 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
 PURSUANT TO
 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 (18 U.S.C. SECTION 1350)
 
 In connection with the Annual Report of Target Acquisitions I, Inc., a Delaware corporation (the "Company"), on Form 10-K/A (Amendment No. 2) for the year ended December 31, 2011, as filed with the Securities and Exchange Commission (the "Report"), Changkui Zhu, Chief Executive Officer of the Company, does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. ss. 1350), that:
 
 (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
 Dated: September 18, 2012
 
 /s/ Changkui Zhu
 Changkui Zhu
 Chief Executive Officer (Principal Executive Officer)
 
 [A signed original of this written statement required by Section 906 has been provided to Target Acquisitions I, Inc. and will be retained by Target Acquisitions I, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Center for Advancing Translational Sciences Special Emphasis Panel; NCATS Conference Grant Reviews.                    

*Date:*                         November 3, 2023.                    

*Time:*                         1:00 p.m. to 5:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Marilyn Moore-Hoon, Ph.D., Scientific Review Officer, Scientific Review Branch, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, MSC 4874, Bethesda, MD 20892, (301) 827-9549,                         *mooremar@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: September 29, 2023.

Patricia B. Hansberger,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-22100 Filed 10-4-23; 8:45 am]

BILLING CODE 4140-01-P
AMENDMENT NUMBER 01

                            TO LEASE SCHEDULE NO. 01

TO MASTER LEASE AGREEMENT NO. 11053



That  certain  Lease  Schedule  No. 01 dated  October 15,  1999 to Master  Lease
Agreement No. 11053 between PHYMED Diagnostic Imaging Center Hillcrest,  Inc. as
Lessee  and Prime  Leasing,  Inc.  as  Lessor,  and all  supplemental  documents
thereto,  notwithstanding  anything to the contrary set forth  therein is hereby
amended and it is expressly agreed to as follows:


Section 1, Initial Term is hereby amended to read as follows:

1.  Initial  Term:  49  months,  commencing  with  the  first  day of the  month
immediately  following the  Commencement  Date of the Secured Party's  Temporary
Master Lease Agreement (the "Temporary Master Lease") between Lessee and Lessor,
dated October 15, 1999.


Section 2, Rental Payments is hereby amended to read as follows:

2. Rental Payments:  $33,333 for the first and second month, $0.00 for the third
month  and  $34,656.00  for  month  four  through  forty-nine,  plus any and all
applicable taxes.







Except as expressly set forth  herein,  the Lease  Schedule  shall not otherwise
have been modified or amended hereby.

Accepted and Agreed to:                      Accepted and Agreed to:

Prime Leasing, Inc.                          PHYMED Diagnostic Imaging Center
 (Lessor)                                    Hillcrest, Inc.
                                              (Lessee)

BY:                                          BY:
   ------------------------------------         --------------------------------

NAME:(Printed)                               NAME:(Printed)
               ------------------------                     --------------------

TITLE:                                       TITLE:
      ---------------------------------            -----------------------------

DATE:                                        DATE:
      ---------------------------------            -----------------------------
AMENDMENT
NO. 3 TO


EARLY
ACCESS AGREEMENT


 


This
third Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between
Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each
a “Party” and together the “Parties” to the Agreement, is entered into as of 14 February
2018 (the “Amendment No. 3 Effective Date”).


 


RECITALS


 


WHEREAS,
HEMISPHERX and IMPATIENTS are Parties to the Agreement for HEMISPHERX’S Product, Ampligen (rintatolimod);


 


WHEREAS,
the Agreement has been amended on 13 December 2016 and 28 June 2017;


 


WHEREAS,
the Parties wish to further amend the Agreement to include Canada in the Territory for the limited Field of treatment of pancreatic
cancer, as set forth below;


 


NOW,
THEREFORE, the Parties hereby agree as follows:


 


Definitions
and References. Except as set forth herein, capitalized terms not otherwise defined or amended in the Amendment shall have
the meaning ascribed to them in the Agreement. References to Articles or Sections are the same with all of their subparts as they
appear in the Agreement.


 


	1.	Amendment
    to the Agreement: Effective as of the Amendment No. 3 Effective Date, the Agreement shall be amended as follows:


 


	 	1.1.	The
    definition of Territory in Clause 1.10 of the Agreement shall be amended to read:
	 	 	 
	 	 	“Field”
    means treatment of chronic fatigue syndrome and/or the treatment of pancreatic cancer. For Canada the Field shall be limited
    to treatment of pancreatic cancer only.
	 	 	 
	 	1.2.	The
    definition of Territory in Clause 1.31 of the Agreement shall be amended to read:
	 	 	 
	 	 	“Territory”
    means all countries of the European Union, The United Kingdom following a Brexit, Turkey and Canada.


 


	2.	Effect
    of the Amendment. From and after the Amendment No. 3 Effective Date, all references to the Agreement shall mean the Agreement
    as amended by this Amendment. Except as expressly amended by the Amendment, all of the provisions of the original Early Access
    Agreement shall remain in full force and effect. 


 




    	 	1	 



     


    

 


IN
WITNESS WHEREOF, the respective Parties hereto have duly executed this Amendment as of the Amendment No. 3 Effective Date
above. The persons executing this Amendment represent and warrant that they have the full power and authority to enter into this
Amendment on behalf of the persons or entities for whom they are signing.


 


	HEMISPHERX BIOPHARMA, INC.	 
	a Delaware corporation	 
	 	 
	By:	/s/ Ronald
    Brus, MD	 
	Title:	CEO	 


 


	IMPATIENTS N.V.	 
	a Dutch limited liability company	 
	 	 
	By:	/s/ Thomas
    K. Equals	 
	Title:	Chairman
    and CEO	 


 




    	 	2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 ORDER FOR DISMISSING COMPLAINT/BAKER - 1

05-5221M

UNITED STATES ATTORNEY

700 STEWART STREET, SUITE 5220

SEATTLE, WASHINGTON 98101-1271

(206) 553-7970

Magistrate Judge Arnold

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT TACOMA

UNITED STATES OF AMERICA, )

) NO. 05-5221M

Plaintiff, )

)

v. ) ORDER TO DISMISS COMPLAINT 

) AND QUASH ARREST WARRANT 

TRAVIS WAYNE BAKER, )

)

Defendant. ) 

_________________________________)

Based on the Motion brought by the government, it is hereby

ORDERED

The criminal complaint against TRAVIS WAYNE BAKER, is hereby dismissed, and

FURTHER, the arrest warrant for TRAVIS WAYNE BAKER is herein QUASHED.

DATED this 13th day of December, 2005.

 /s/ J. Kelley Arnold UNITED STATES MAGISTRATE JUDGE

Presented by:

s/Carl Blackstone CARL BLACKSTONE

Assistant United States Attorney

Case 3:05-mj-05221-JKA Document 15 Filed 12/13/05 Page 1 of 1
### Page 1 of 3 **Disposition Comments Docket No:**  

### FAA - 20 1 5 - 4803 These comments are in **Directorate ID:** 

### 20 1 5 - CE - 0 3 4 - AD response to an SNPRM Originating Office Tracking No.: **Next Step:** FRAN SNPRM 

### N o C omments/Only

Supportive Comments Received

– If this box is checked, no signatures are required. No 

### Has the reference d service information been revised since the NPRM was issued? I f ye s, lis t latest revision and attach a cop y. Note that changes beyond the scope of the previously published NPRM will require a new notice. Contact the Directorate focal point for guidance. Instructions: Summarize all comments **by issue** (not by commenter) and provide your recommended resolution of each issue. **All comments relating to the sam e issue should be discussed together.**  Do not list all of the issues from one commenter together. If changes to the AD are required based on the comments received, explain why and describe in detail what change(s) you recommend. Reference FAA - IR- M - 8040.1C Chapter 9. **ISSUE 1:** Select one o

f the following : If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because

Make the following changes to the AD: If **NO** , we don’t agree because **ISSUE 2**  **:** Select one of the following :

If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because Make the following changes to the AD:

### Page 2 of 3

If **NO** , we don’t agree because **For additional issues, do uble**  **- click**  **here**

### Page 3 of 3 **S ignature Section**  Signature indicates concurrence with this action. Originating Office Tracking No.: **ASE** Printed Name **: Date** 

**Branch M anager**  **Date**
Exhibit 31.1

                           SECTION 302 CERTIFICATION

I, Mark A. Smith, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Bion
Environmental Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
of the small business issuer as of, and for, the periods presented in this
report;

4.   I am responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for
the small business issuer and have:

     (a)  Designed such disclosure controls and procedures or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the small business issuer,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;

     (b)  Evaluated the effectiveness of the small business issuer's
disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such
evaluation; and

     (c)  Disclosed in this report any change in the small business issuer's
internal control over financial reporting that occurred during the small
business issuer's most recent fiscal quarter (the small business issuer's
fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the small business
issuer's internal control over financial reporting; and

5.   I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the small business issuer's auditors and
the audit committee of the small business issuer's board of directors (or
persons performing the equivalent functions):

     (a)  All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the small business issuer's ability to
record, process, summarize and report financial information; and

     (b)  Any fraud, whether or not material, that involves management or
other employees who have a significant role in the small business issuer's
internal control over financial reporting.

Date: February 6, 2008



/s/ Mark A. Smith
Mark A. Smith
Chief Executive Officer and
Principal Financial Officer
No. 57772.

protests 180654-K, etc. (Providence).

#### Prouvost Lefebvre of Rhode Island, Inc. *v.*United States,

Opinion by

Oliver, C. J.

It was stipulated that for duty purposes the clean content of the wool in question was determined in accordance with the instructions contained in T. D. 53159. Said T. D. 53159 was issued following the decision in *Fred Whitaker Company, Inc.*v. *United States*(27 Cust. Ct. 168, C. D. 1365), affirmed in *United States*v. *Fred Whitaker Company, Inc.*(40 C. C. P. A. 19, C. A. D. 492), wherein the statutory language, clean content of wool, as used in paragraph 1102 (b), was construed to mean the product commercially usable as wool and from which all the weight of grease and foreign material has been removed, including the wool fibers which are unavoidably and irrevocably lost as a result of commercially applied cleaning processes. Accordingly, the wool in question was held dutiable at the rate applied by the collector on the basis of the percentages of clean content as set forth in the column headed “Clean Content under T. D. 53159” in the schedule attached to and made a part of the decision in this case.
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Order to Continue Trial Date/

MARAMBA, et al/CR06-106RSM — 1 UNITED STATES ATTORNEY

700 Stewart Street, Suite 5220

Seattle, Washington 98101-1271

(206) 553-7970

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT SEATTLE

UNITED STATES OF AMERICA, )

) CASE NO. CR06-106RSM

 Plaintiff, )

)

v. ) ORDER REGARDING 

) CONTINUANCE OF TRIAL

) TO JANUARY 22, 2007

)

FELIPE MARAMBA, )

ELEAZAR BASILIO, and )

JERRY RACCA, )

)

 Defendants. ) )

The Court’s Order granting a continuance of trial in this matter (Dkt. No. 197)

applies to all defendants in this matter who have not yet pleaded guilty. 

IT IS HEREBY ORDERED that trial in this matter for all defendants pending trial

is continued from November 20, 2006 to January 22, 2007. Pretrial motions for all

defendants who have not yet pleaded guilty are due on December 22, 2006.

//

//

Case 2:06-cr-00106-RSM Document 201 Filed 11/13/06 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Order to Continue Trial Date/

MARAMBA, et al/CR06-106RSM — 2 UNITED STATES ATTORNEY

700 Stewart Street, Suite 5220

Seattle, Washington 98101-1271

(206) 553-7970

IT IS FURTHER ORDERED that, for purposes of computing the time limitations 

imposed by the Speedy Trial Act, 18 U.S.C. §§ 3161-3164, the period of delay from 

November 20, 2006, up to and including January 22, 2007, is excludable time pursuant to 

18 U.S.C. § 3161(h)(8)(B)(iv).

DATED this 13 day of November, 2006.

A

RICARDO S. MARTINEZ

UNITED STATES DISTRICT JUDGE

Presented by:

 /s Jill Otake 

JILL OTAKE

Assistant United States Attorney

WA Bar # 28298

United States Attorney’s Office

700 Stewart Street, Suite 5220

Seattle, WA 98101

Telephone: (206) 553-4254

Fax: (206) 553-0755

E-mail: jill.otake@usdoj.gov

Case 2:06-cr-00106-RSM Document 201 Filed 11/13/06 Page 2 of 2
November 7, 1962

No. 67182.

Appeal 5083.

#### R. W. Smith et al. *v.*United States.

C.D. 2250 reversed August 2, 1962. C.A.D. 806.
<TABLE> <S> <C>


<ARTICLE>                   5
<LEGEND>
</LEGEND>
<CIK>                       0000875579
<NAME>                      Spectrum Pharmaceutical Corporation
<MULTIPLIER>                                                          1
<CURRENCY>                                                   US Dollars

<S>                            <C>
<PERIOD-TYPE>                  3-MOS
<FISCAL-YEAR-END>                                           MAR-31-2000
<PERIOD-START>                                              APR-01-1999
<PERIOD-END>                                                JUN-30-1999
<EXCHANGE-RATE>                                                       1
<CASH>                                                                0
<SECURITIES>                                                          0
<RECEIVABLES>                                                         0
<ALLOWANCES>                                                          0
<INVENTORY>                                                           0
<CURRENT-ASSETS>                                                      0
<PP&E>                                                                0
<DEPRECIATION>                                                        0
<TOTAL-ASSETS>                                                        0
<CURRENT-LIABILITIES>                                                 0
<BONDS>                                                               0
<PREFERRED-MANDATORY>                                                 0
<PREFERRED>                                                           0
<COMMON>                                                             76
<OTHER-SE>                                                          (76)
<TOTAL-LIABILITY-AND-EQUITY>                                          0
<SALES>                                                               0
<TOTAL-REVENUES>                                                      0
<CGS>                                                                 0
<TOTAL-COSTS>                                                     18000
<OTHER-EXPENSES>                                                (530000)
<LOSS-PROVISION>                                                      0
<INTEREST-EXPENSE>                                                    0
<INCOME-PRETAX>                                                       0
<INCOME-TAX>                                                          0
<INCOME-CONTINUING>                                              512000
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                     512000
<EPS-BASIC>                                                      0.21
<EPS-DILUTED>                                                      0.21



</TABLE>
EPA SANITIZED Page 1 of 10
EPA SANITIZED Page 2 of 10
 

 

 

 

EPA SANITIZED Page 3 of 10
EPA SANITIZED Page 4 of 10
 

EPA SANITIZED Page 5 of 10
EPA SANITIZED Page 6 of 10
EPA SANITIZED Page 7 of 10
 

 

EPA SANITIZED Page 8 of 10
EPA SANITIZED Page 9 of 10
 EPA SANITIZED Page 10 of 10
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 ORDER

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT TACOMA

RONALD L. BASKETT,

Plaintiff,

v.

STATE OF WASHINGTON et al.,

Defendants.

Case No. C06-5130FDB

ORDER DENYING PENDING

MOTIONS 

This civil rights action has been referred to the undersigned Magistrate Judge pursuant to

Title 28 U.S.C. § 636(b)(1)(B). Plaintiff was given leave to proceed in forma pauperis. Before the

court are three motions filed by plaintiff between March 31st, 2006 and April 20th, 2006. Plaintiff

asks for “clarification” of his own exhibits, appointment of a guardian ad litem, and for an injunction

forcing prison officials to transfer him to a work camp. (Dkt. # 7, 8, and 9). 

The court found the complaint filed in this case to be deficient and has ordered plaintiff to file

an amended complaint curing the defect if possible by May 26th, 2006. (Dkt. # 10).

The “clarification” the plaintiff seeks is for this court to tell him who signed an order dealing

with an in forma pauperis application in state court. (Dkt. # 7). 

Plaintiff’s motions are DENIED.

Case 3:06-cv-05130-FDB Document 12 Filed 05/03/06 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 ORDER

It is not the courts duty to interpret plaintiff’s exhibits for him and the court is not a witness. 

Further, the court does not have an acceptable complaint before it at this time and will not consider

motions for a guardian or motions for injunctive relief until such time as there is a viable complaint.

The Clerk is directed to send plaintiff a copy of this Order.

DATED this 3rd day of May, 2006.

/S/ J. Kelley Arnold

J. Kelley Arnold

United States Magistrate Judge

Case 3:06-cv-05130-FDB Document 12 Filed 05/03/06 Page 2 of 2